Etravirine as a Switching Option for Patients with HIV RNA Suppression: A Review of Recent Trials
Table 4
UK SSAT029 trial: changes in CNS adverse events by treatment arm, to Week 12.
Etravirine
Efavirenz
Grades 2–4 CNS adverse events
All Grades 2–4 CNS adverse events
60%
81%
Median number of CNS adverse events
1
3
Dizziness
15%
19%
Depression
20%
19%
Insomnia
37%
60%
Anxiety
25%
44%
Impaired concentration
30%
31%
Headache
5%
25%
Somnolence
30%
31%
Fatigue
35%
44%
Abnormal dreams
20%
63%
Nervousness
9%
29%
Hallucinations
0%
7%
Patients in the delayed (efavirenz) arm switched to etravirine at Week 12; patients in the immediate etravirine arm remained on etravirine after Week 12.